Jason Gerberry

This Organon Analyst Is Bearish On Heels Of Health Care Company's Merck Spinoff
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate'
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate'
Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal

Jason Gerberry Recent News

BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'
Following the recent rally, Alkermes Plc’s (NASDAQ: ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities.
3 Reasons To Buy Organon Stock, Says BofA Analyst
Organon & Co (NYSE: OGN), which has recently spun-off from Merck & Co., Inc.
FibroGen Analyst Removes Roxadustat Sales From Model After AdCom Snub
FibroGen, Inc.
JNJ's $260M Settlement Could Serve As Global Opioid Deal Template: Analyst
Over the weekend, Johnson & Johnson (NYSE: JNJ) reached a major opioid litigation settlement that could have broader implications for the biopharmaceutical industry.
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Why did BofA Downgrade Bausch Health?
There are challenges to value creation in the proposed separation of Bausch Health Companies Inc’s (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Securities.
Teva Analyst Estimates $1B In Price Fixing Liability Following DOJ Indictment
On Tuesday, the Wall Street Journal reported the U.S.
BofA Raises Jazz Pharma Estimates After Zepzelca Update
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities.
3 Analysts Dissect Teva's Q4 Results
New York Opioid Case A Significant Risk For Pharma Stocks, Says Bearish BofA
Bausch Analyst Sees Challenging Setup For Next Leg Of Recovery Story
Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential
Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts
Analysts Cut AbbVie Price Targets After Earnings Miss
BofA Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results
Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Making Sympathy Moves
Analysts Call Verrica A Buy For Vast Molluscum Opportunity
Jazz Pharma Investors: Did You Catch This Favorable Ruling?
3 Mega Biotechs Leerink Loves
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
The Wall Street Research Making Waves Today